Piramal Pharma Solutions unveils high-throughput screening facility in Ahmedabad
Piramal Pharma Limited’s Pharma Solutions (PPS) business, a prominent Contract Development and Manufacturing Organization (CDMO), marks a new milestone with the introduction of a state-of-the-art high-throughput screening facility in Ahmedabad, India. This expansion elevates primary and secondary screening capacities for compounds formulated at this specific site.
Holistic Discovery Capabilities
Aiming to redefine drug discovery services, this latest move by PPS offers clients an integrated suite of discovery capabilities. Utilizing advanced in-vitro screening technology tools, PPS looks forward to generating superior data packages, enhancing their stature as a preferred outsourcing ally. The unification of chemistry and biology services promises heightened efficiency in the discovery trajectory, yielding an enriched experience for PPS clientele. In sync with this growth, PPS is geared to onboard seasoned professionals skilled in biology services, further bolstering the existing technical and operational competencies.
CEO’s Insight
Peter DeYoung, CEO of Piramal Pharma Solutions, elucidated on the venture, stating, “These advanced in-vitro biology offerings empower our drug discovery team to relay critical decision-making information to clients at early stages, solidifying our role as a pivotal partner in the drug discovery journey.”
Technical Overview
The contemporary high-throughput screening model equips PPS with the capability to assess vast collections via diverse assay platform technologies. These encompass TR-FRET/HTRF, Fluorescence Polarization, absorbance, Luminescence/Electrochemiluminescence, AlphaScreen, LanthaScreen, flow cytometry, and high-content imaging, suitable for a spectrum of targets, notably G-Protein-Coupled Receptors (GPCRs) and kinases.
Conclusion
With this strategic expansion, Piramal Pharma Solutions further entrenches its commitment to advancing drug discovery, promising a streamlined and effective process for its partners and customers in the pharmaceutical domain.